


First quarter

CEO Christer Wahlquist
CFO Per-Ola Holmström


6 May, 2025



Medical Solutions




Engineered Solutions



Q1 summary – Nolato Group

- Sales amounted to SEK 2,453 million (2,442)
 - Adjusted for currency, a decrease of 1%
 - Growth for Medical Solutions but lower sales for Engineered Solutions
- Operating profit (EBITA) rose by 14% to SEK 271 million (238)
- Sharply increased EBITA margin to 11.0% (9.7)
 - Strengthened margin in both business areas but particularly strong performance for Medical Solutions
- Cash flow from operating activities amounted to SEK 135 million (136)
- Net financial liabilities in relation to adjusted operating profit (EBITDA) was 0.5x

A global solutions provider established on three continents



One Group – two business areas

Nolato

Our offering as a strategic partner for selected global customers comprises development and production, primarily in the field of polymers, along the entire value chain.

2,453

SALES
SEKm
Q1

271

EBITA
SEKm
Q1

11.0

EBITA MARGIN
%
Q1

Medical Solutions

Development and manufacture of complex product systems and components for medical devices, the pharmaceutical industry and diagnostics.

1,397

SALES
SEKm
Q1

171

EBITA
SEKm
Q1

12.2

EBITA MARGIN
%
Q1

Engineered Solutions

Design, development, industrialization and manufacture of advanced components, subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions.

1,058

SALES
SEKm
Q1


107

EBITA
SEKm
Q1

10.1

EBITA MARGIN
%
Q1

Medical Solutions – sustainable growth and global expansion




Medical Solutions – focused product areas

Pharma

Diagnostics

Medical Devices




Medical Solutions – Q1


- Sales growth of 3%
 - Adjusted for currency an increase of 2%
 - Most market areas experienced stable volumes
 - Drug Delivery market area continued to grow
 - Surgery stabilized
 - IVD showed lower volumes
- EBITA margin of 12.2% (10.3)
 - Strong margin improvement of a full 1.9 percentage points
 - Improved margin particularly in US operations
 - * cost adjustments
 - * focus on the entire supply chain
- Expansion in Hungary linked to our significant customer contract is proceeding according to plan
- Acquisition of property in Poland enables continued expansion in Europe

SEKm	Q1		Full year	
	2025	2024	2024	2023
Sales	1,397	1,355	5,434	5,308
Operating profit (EBITA)	171	140	586	525
EBITA margin (%)	12.2	10.3	10.8	9.9
Operating profit (EBIT)	163	132	553	494


Sales




EBITA



EBITA margin




Sales per market area, Q1




Engineered Solutions — advanced technology and high-productivity manufacturing



1,058 SALES SEKm, Q1	107 EBITA SEKm, Q1
43 SHARE OF THE GROUP %, Q1	10.1 EBITA MARGIN %, Q1



Engineered Solutions – focused product areas




Engineered Solutions – Q1


- Sales decrease of 3%
 - Adjusted for currency, a decrease of 3%
 - As expected, volumes to the Automotive industry declined
 - Other market areas had stable volumes
 - Materials business showed sharply increased volumes and growth was a strong 12% (currency adjusted)
- EBITA margin of 10.1% (9.5)
 - Favorable product mix
 - Cost adjustments

SEKm	Q1		Full year	
	2025	2024	2024	2023
Sales	1,058	1,087	4,243	4,245
Operating profit (EBITA)	107	103	409	266
EBITA margin (%)	10.1	9.5	9.6	6.3
Operating profit (EBIT)	104	100	397	253


SALES




EBITA



EBITA margin



Sales per market area, Q1



Group financial highlights

SEKm	Q1 2025	Q1 2024	R12M	Full year 2024
Net sales	2,453	2,442	9,675	9,664
Operating profit (EBITA)	271	238	991	958
EBITA margin (%)	11.0	9.7	10.2	9.9
Profit after financial income and expense	252	209	891	848
Profit after tax	199	162	695	658
Effective tax (%)	21.0	22.5	22.0	22.4
Cash flow from operating activities	135	136	1,376	1,377
Net investments affecting cash flow, excl. acquisitions and disposals	271	230	677	636
Cash flow after investments, excl. acquisitions and disposals	-136	-92	699	743
Earnings per share (SEK)	0.74	0.60	2.58	2.44
Equity/assets ratio (%)	59	57	59	59
Net financial liabilities, excl. pension & lease liabilities	757	1,026	757	671
Return on capital employed (%)	12.7	9.5	12.7	12.3
Net financial liabilities in relation to adjusted EBITDA (x)	-	-	0.5	0.4



Current situation

Medical Solutions



- Maintained growth strategy
- Focus on margin – cost adjustments, pricing strategy and efficiency
- Innovation and sustainability
- Broad customer base with longstanding, close customer relationships
- Significant customer contracts validate overall strategy

Engineered Solutions



- Advanced market positions
- Established position in new product areas
- Focus on innovative and sustainable solutions
- Success in new markets positive for Materials (EMC)

Thank you.



This presentation may contain forward-looking statements. When used in this presentation, words such as “anticipate”, “believe”, “estimate”, “expect”, “plan” and “project” are intended to identify forward-looking statements. Such statements could encompass risks and uncertainties pertaining to product demand, market acceptance, effects of economic conditions, impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nolato’s management as of the date made with respect to future events but are subject to risks and uncertainties. While all of these forward-looking statements are based on estimates and assumptions made by Nolato’s management and are believed to be reasonable, they are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements. Nolato disclaims any intention or obligation to update these forward-looking statements.

